Biosimilars in Developed and Developing East and Southeast Asian Countries: Japan, South Korea, and Malaysia—Overview, Evolution, and Regulations Assessment

<div>Global sales at risk due to loss of patents (2006–2020). Source: EvaluatePharma, 2014 [<a href="/journals/bmri/2016/5910403/#B2">2</a>].</div>

BioMed Research International

fig1

Figure 1

Figure 1: Biosimilars in Developed and Developing East and Southeast Asian Countries: Japan, South Korea, and Malaysia—Overview, Evolution, and Regulations Assessment 

Figure 1 | Biosimilars in Developed and Developing East and Southeast Asian Countries: Japan, South Korea, and Malaysia—Overview, Evolution, and Regulations Assessment 